Lakefront Biotherapeutics | GLPG - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
argenx SE USD 1.18B 40.98M 2026-03
AstraZeneca USD 12.61B 225M 2026-03
Biogen USD 1.82B 169.5M 2026-03
Genmab DKK 977M 13M 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
GRIFOLS EUR 686.84M 56.95M 2025-12
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Incyte USD 1.17B 217.51M 2026-03
Merck EUR 3.07B 104M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
UCB EUR 3.19B 621M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03